1. Home
  2. MLYS
  3. MLYS News

Latest Mineralys Therapeutics Inc. (MLYS) News on October 20, 2025

Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial
MLYS

Simply Wall St.

17 days ago

Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial

Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups
MLYS

Insider Monkey

20 days ago

Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
MLYS

Motley Fool

a month ago

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

MLYS

MT Newswires

4 months ago

Mineralys Phase 2 Trial of Hypertension, Kidney Disease Drug Meets Primary Endpoint; Shares Up Pre-Bell

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
MLYS

GlobeNewswire

4 months ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

MLYS

MT Newswires

4 months ago

Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target

Mineralys announces late-breaking presentation of data from Launch-HTN trial
MLYS

TipRanks

5 months ago

Mineralys announces late-breaking presentation of data from Launch-HTN trial

Mineralys reports outcomes from trial of lorundrostat for hypertension
MLYS

Clinical Trials Arena

5 months ago

Mineralys reports outcomes from trial of lorundrostat for hypertension

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
MLYS

GlobeNewswire

5 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
MLYS

Zacks

5 months ago

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
MLYS

GlobeNewswire

5 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
MLYS

Zacks

5 months ago

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy

MLYS

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Mineralys Therapeutics Inc Earnings Call

MLYS

GuruFocus.com

5 months ago

Mineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

MLYS

MT Newswires

5 months ago

Mineralys Therapeutics Q1 GAAP Loss Widens

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
MLYS

GlobeNewswire

5 months ago

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
MLYS

GlobeNewswire

5 months ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
MLYS

GlobeNewswire

5 months ago

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
MLYS

GlobeNewswire

6 months ago

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns
MLYS

Simply Wall St.

6 months ago

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns

MLYS

MT Newswires

7 months ago

Mineralys Therapeutics Insider Sold Shares Worth $879,008, According to a Recent SEC Filing

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
MLYS

GlobeNewswire

7 months ago

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March
MLYS

Insider Monkey

7 months ago

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
MLYS

GlobeNewswire

7 months ago

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?
MLYS

Insider Monkey

7 months ago

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
MLYS

GlobeNewswire

7 months ago

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

MLYS

MT Newswires

7 months ago

Mineralys Therapeutics Insider Bought Shares Worth $8,100,000, According to a Recent SEC Filing

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
MLYS

GlobeNewswire

7 months ago

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

MLYS

MT Newswires

7 months ago

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

MLYS

MT Newswires

7 months ago

Mineralys Therapeutics Prices $175 Million Share Offering

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
MLYS

GlobeNewswire

7 months ago

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

MLYS

MT Newswires

7 months ago

Mineralys Therapeutics Launches $250 Million Public Offering of Shares

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
MLYS

GlobeNewswire

7 months ago

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

MLYS

MT Newswires

7 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

MLYS

MT Newswires

7 months ago

Top Midday Gainers

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
MLYS

Benzinga

7 months ago

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Mineralys’s stock soars as hypertension pill scores in two pivotal trials
MLYS

Clinical Trials Arena

7 months ago

Mineralys’s stock soars as hypertension pill scores in two pivotal trials

MLYS

MT Newswires

7 months ago

Mineralys Therapeutics Says Lorundrostat Met Trial Endpoints for Treating Hypertension; Shares Up Pre-Bell

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
MLYS

GlobeNewswire

7 months ago

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
MLYS

GlobeNewswire

7 months ago

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

MLYS

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Mineralys Therapeutics Inc Earnings Call

MLYS

GuruFocus.com

8 months ago

Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ...

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
MLYS

GlobeNewswire

8 months ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
MLYS

GlobeNewswire

8 months ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

MLYS

MT Newswires

9 months ago

Mineralys Completes Enrollment in Mid-Stage Hypertension Trial

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
MLYS

GlobeNewswire

9 months ago

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials
MLYS

TipRanks

9 months ago

Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
MLYS

GlobeNewswire

9 months ago

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Mineralys Therapeutics Announces Q3 2024 Results and Updates
MLYS

TipRanks

a year ago

Mineralys Therapeutics Announces Q3 2024 Results and Updates

MLYS

Thomson Reuters StreetEvents

a year ago

Q3 2024 Mineralys Therapeutics Inc Earnings Call

MLYS

MT Newswires

a year ago

Mineralys Therapeutics Q3 Net Loss Widens

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in Upcoming Investor Conferences
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
MLYS

GlobeNewswire

a year ago

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
MLYS

Simply Wall St.

a year ago

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares
MLYS

GuruFocus.com

a year ago

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares

Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares
MLYS

GuruFocus.com

a year ago

Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares

MLYS

MT Newswires

a year ago

HC Wainwright Initiates Mineralys Therapeutics at Buy Rating With $30 Price Target

Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)
MLYS

GuruFocus.com

a year ago

Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)

MLYS

MT Newswires

a year ago

Mineralys Therapeutics Insider Sold Shares Worth $592,022, According to a Recent SEC Filing

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares
MLYS

GuruFocus.com

a year ago

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)
MLYS

GuruFocus.com

a year ago

Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)

MLYS

MT Newswires

a year ago

Mineralys Therapeutics Insider Sold Shares Worth $1,252,718, According to a Recent SEC Filing

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
MLYS

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
MLYS

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
MLYS

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
MLYS

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
MLYS

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
MLYS

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
MLYS

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?
MLYS

Simply Wall St.

a year ago

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses
MLYS

Investor's Business Daily

a year ago

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library
MLYS

Business Wire

a year ago

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap
MLYS

Investor's Business Daily

a year ago

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

EnviroGold Global Closes First Tranche of Private Placement
MLYS

GlobeNewswire

a year ago

EnviroGold Global Closes First Tranche of Private Placement

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)
MLYS

GuruFocus.com

a year ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

How markets digested hot jobs print: Top takeaways
MLYS

Yahoo Finance Video

a year ago

How markets digested hot jobs print: Top takeaways

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
MLYS

GlobeNewswire

a year ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"
MLYS

PR Newswire

a year ago

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript
MLYS

Insider Monkey

a year ago

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript

We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth
MLYS

Simply Wall St.

a year ago

We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
MLYS

GlobeNewswire

a year ago

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
MLYS

TipRanks

2 years ago

Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
MLYS

Insider Monkey

2 years ago

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript

MLYS

GuruFocus.com

2 years ago

Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MLYS

GlobeNewswire

2 years ago

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
MLYS

GlobeNewswire

2 years ago

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

Mineralys Therapeutics Announces $120 Million Private Placement Financing
MLYS

GlobeNewswire

2 years ago

Mineralys Therapeutics Announces $120 Million Private Placement Financing

Editas Medicine to Participate in Upcoming Investor Conferences
MLYS

GlobeNewswire

2 years ago

Editas Medicine to Participate in Upcoming Investor Conferences

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
MLYS

GlobeNewswire

2 years ago

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

Share on Social Networks: